Cargando…

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is an aggressive human cancer and is caused as consequences of chronic liver diseases. Although HCC is more common in patients with cirrhosis, there is increasing evidence that this cancer may develop in the setting of noncirrhotic nonalcoholic steatohe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutiérrez-Cuevas, Jorge, Lucano-Landeros, Silvia, López-Cifuentes, Daniel, Santos, Arturo, Armendariz-Borunda, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818030/ https://www.ncbi.nlm.nih.gov/pubmed/36612019 http://dx.doi.org/10.3390/cancers15010023

Ejemplares similares

Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects
por: Galicia-Moreno, Marina, et al.
Publicado: (2020)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2021)

Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models
por: Galicia-Moreno, Marina, et al.
Publicado: (2021)

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio
por: Silva-Gomez, Jorge Antonio, et al.
Publicado: (2021)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
por: Escutia-Gutiérrez, Rebeca, et al.
Publicado: (2021)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
por: Sandoval‐Rodriguez, Ana, et al.
Publicado: (2020)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
por: Martinez-Alvarado, Yocasta, et al.
Publicado: (2023)

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C
por: Flores-Contreras, Lucia, et al.
Publicado: (2014)

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
por: Yu, Simiao, et al.
Publicado: (2022)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

AdhMMP8 Vector Administration in Muscle: An Alternate Strategy to Regress Hepatic Fibrosis
por: García-Bañuelos, Jesús, et al.
Publicado: (2023)

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021)

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
por: Motta, Benedetta Maria, et al.
Publicado: (2023)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Sandoval-Rodriguez, Ana, et al.
Publicado: (2022)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
por: Shao, Gaoxuan, et al.
Publicado: (2022)

Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
por: Boslem, Ebru, et al.
Publicado: (2023)

An Update in Epigenetics in Metabolic-Associated Fatty Liver Disease
por: Rodríguez-Sanabria, J. Samael, et al.
Publicado: (2022)

Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2021)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
por: De Minicis, Samuele, et al.
Publicado: (2014)

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
por: Grohmann, Marcus, et al.
Publicado: (2018)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
por: Ge, Chenxu, et al.
Publicado: (2022)

Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC)
por: Zhao, Pin, et al.
Publicado: (2021)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

The Role of NRF2 in Obesity-Associated Cardiovascular Risk Factors
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2022)

The Epigenetic Regulation of HCC Metastasis
por: Han, Tae-Su, et al.
Publicado: (2018)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

Erratum for the Research Article: “Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC”
Publicado: (2023)

Unraveling the molecular links between benzopyrene exposure, NASH, and HCC: an integrated bioinformatics and experimental study
por: Yang, Zheming, et al.
Publicado: (2023)

Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC
por: Ande, Sudharsana R., et al.
Publicado: (2016)

Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis
por: Huang, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ne2groektnvm3mmr164djmfpeb